Timp2 loss-of-function mutation and TIMP2 treatment in murine model of NSCLC: modulation of immunosuppression and oncogenic signaling
D. Peeney, S. Kumar, T. P. Singh, Y. Liu, S. Jensen, A. Chowdhury, S. Coates-Park, J. Rich, S. Gurung, Y. Fan, D. Meerzaman, W. G. Stetler-Stevenson
TIMP2 treatment compensates for TIMP2 mutation to reveal immunomodulatory and oncogene regulation that inhibits tumor growth and metastatic niche formation.
bioRxiv · Dec 29, 2023Cancer Biology